SAFETY DATA SHEET

Prepared to U.S. OSHA, CMA, ANSI, Canadian WHMIS Standards, and the Global Harmonization Standard

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY UNDERTAKING

IDENTIFICATION of the SUBSTANCE or PREPARATION:

TRADE NAME (AS LABELED): NOVUS PLASTIC POLISH #2
PRODUCT CODE: 7030, 7032, 7033, 7072
CHEMICAL NAME/CLASS: Aqueous Silica/Hydrocarbon Mixture
U.N. NUMBER: Not Applicable
U.N. DANGEROUS GOODS CLASS/SUBSIDARY RISK: Not Applicable
RELEVANT USES of the SUBSTANCE:
Clean and Restore Plastic Surfaces
USES ADVISED AGAINST:
Other than Relevant Use, Including Glass Polishing

COMPANY/UNDERTAKING IDENTIFICATION:

U.S./DISTRIBUTOR’S NAME: NOVUS, INC.
ADDRESS: 650 Pelham Boulevard, Suite 100
St Paul, MN  55114
EMERGENCY PHONE (medical): 1-800-420-8036
EMERGENCY PHONE (transport):
United States/Canada/Puerto Rico: 1-800/424-9300 (Chemtrec) [24-hrs]
International: 1-703-527-3887 (Chemtrec) [24-hours]
EMAIL ADDRESS FOR SDS INFORMATION: msds-info@novusglass.com
DATE OF PREPARATION: April 22, 2005
DATE OF REVISION: February 9, 2015

2. HAZARD IDENTIFICATION

OSHA HAZARD COMMUNICATION (GLOBAL HARMONIZATION) LABELING AND CLASSIFICATION: This product would be classified as follows, per OSHA’s Hazard Communication Standard (29CFR §1910.1200). This is a self-classification.
Classification: Eye Irritation Cat. 2A, Skin Irritation Cat. 2, STOT (Inhalation-Respiratory Irritation) SE Cat. 3, STOT (Inhalation) RE Cat. 2
Signal Word: Warning
Hazard Statement Codes: H319, H315, H335, H373
Hazard Symbols/Pictograms: GHS08, GHS07

See Section 16 for a full definition of Hazard and Precautionary Statements.

EMERGENCY OVERVIEW: Product Description: This product is an opaque, tan, viscous liquid with a slight, solvent odor. Health Hazards: This product may mildly irritate contaminated tissue, especially upon prolonged exposure. Inhalation of high concentrations of vapors can cause central nervous system depression (e.g., dizziness, headaches, and nausea). This product may contain Crystalline Silica, which is known to cause cancer by inhalation when particles are present. If this product is used in a manner that creates dust, use of respiratory protection is required. Contains compound that is a suspect mutagen. Flammability Hazards: This product must be substantially preheated before ignition can occur. In the event of a fire this product may decompose to release irritating vapors and toxic gases (e.g., silicon, nitrogen and carbon oxides). Reactivity Hazards: This product is not reactive. Environmental Hazards: Releases of this product to the environment, especially in large quantity, may result in environmental damage. Emergency Recommendations: Emergency responders must wear personal protective equipment suitable for the situation to which they are responding.
### 3. COMPOSITION and INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS #</th>
<th>W/W %</th>
<th>Hazard Symbol</th>
<th>Classification Risk Phrases/Hazard Statements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odorless Mineral Spirits</td>
<td>64742-48-9</td>
<td>7.0-13.0%</td>
<td></td>
<td>Due to the fact that this Mineral Spirits contains less than 0.1% benzene or other aromatic, H350 and H340 are not applicable. Classification: Aspiration Toxicity Cat. 1 Hazard Statement Codes: H304 Hazard Symbols/Pictograms: GHS08</td>
</tr>
<tr>
<td>Amorphous Silicas/Diatomaceous Earths Mixture</td>
<td>68855-54-9</td>
<td>5.0-10.0%</td>
<td></td>
<td>SELF CLASSIFICATION Classification: Skin Irritation Cat. 2, Eye Irritation Cat. 2A, STOT (Inhalation-Respiratory Irritation) SE Cat. 3 Hazard Statement Codes: H315, H319, H335 Hazard Symbols/Pictograms: GHS07</td>
</tr>
<tr>
<td>Polydimethyl Siloxane</td>
<td>63148-62-9</td>
<td>4.0-8.0%</td>
<td></td>
<td>Classification: Not Applicable</td>
</tr>
<tr>
<td>Morpholine</td>
<td>110-91-8</td>
<td>1.0-5.0%</td>
<td></td>
<td>Classification: Flammable Liquid Cat. 3, Acute Inhalation Toxicity Cat. 4, Acute Dermal Toxicity Cat. 4, Acute Oral Toxicity Cat. 4, Skin Corrosion Cat. 1B Hazard Statement Codes: H226, H332, H312, H302, H314 Hazard Symbols/Pictograms: GHS02, GHS05, GHS07</td>
</tr>
<tr>
<td>Oleic Acid</td>
<td>112-80-1</td>
<td>1.0-5.0%</td>
<td></td>
<td>SELF CLASSIFICATION Classification: Skin Irritation Cat. 2 Hazard Statement Codes: H315 Hazard Symbols/Pictograms: GHS07</td>
</tr>
<tr>
<td>Crystalline Silicas Mixture</td>
<td>14464-46-1</td>
<td>0.5-0.0%</td>
<td></td>
<td>SELF CLASSIFICATION Classification: STOT (Inhalation-Lung Damage) RE Cat. 2 Hazard Statement Codes: H373 Hazard Symbols/Pictograms: GHS08</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>Balance</td>
<td></td>
<td>Classification: Not applicable.</td>
</tr>
</tbody>
</table>

**NOTE (1):** ALL WHMIS required information is included in appropriate sections based on the ANSI Z400.1-2004 format. This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all the information required by the CPR. See Section 16 for a full definition of Hazard and Precautionary Statements.

### 4. FIRST-AID MEASURES

**DESCRIPTION OF FIRST AID MEASURES:** Contaminated individuals must be taken for medical attention if any adverse effects occur. Take a copy of label and SDS to health professional with victim.

**SKIN EXPOSURE:** If this product contaminates the skin, begin decontamination with running water. Minimum flushing is for 20 minutes.

The contaminated individual must seek medical attention if any adverse effects occur after flushing.

**EYE EXPOSURE:** If this product enters the eyes, open contaminated individual's eyes while under gently running water. Use sufficient force to open eyelids. Have contaminated individual "roll" eyes. Minimum flushing is for 20 minutes. Contaminated individual must seek medical attention if adverse effect continues after flushing.

**INHALATION:** If mists or sprays of this product are inhaled, remove victim to fresh air. The contaminated individual must seek medical attention if any adverse effects occur.

**INGESTION:** If this product is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER FOR MOST CURRENT INFORMATION. If professional advice is not available, do not induce vomiting. Never induce vomiting or give diluents (milk or water) to someone who is unconscious, having convulsions, or unable to swallow. If victim is convulsing, maintain an open airway and obtain immediate medical attention.

**MOST IMPORTANT SYMPTOMS/EFFECTS (ACUTE & CHRONIC):** See Sections 2 (Hazard Identification) and 11 (Toxicological Information) for description of possible health effects from exposure to this product.

**MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE:** Skin disorders, respiratory conditions, and central nervous system conditions may be aggravated by prolonged overexposure to this product.

**INDICATION OF IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT IF NEEDED:** Treat symptoms and eliminate overexposure.

### 5. FIRE-FIGHTING MEASURES

**FLASH POINT (Pensky-Martens Closed Tester):** > 93°C (> 199.4°F)

**AUTOIGNITION TEMPERATURE:** Not available.

**FLAMMABLE LIMITS (in air by volume, %):** Not available.

**FIRE EXTINGUISHING MEDIA:** Use extinguishing material suitable to the surrounding fire, including halon, carbon dioxide, dry chemical and ABC class.

**UNSUITABLE FIRE EXTINGUISHING MEDIA:** None known.

---

**NFR A RATING**

**HEALTH**

1 = Minimal

2 = Slight

3 = Moderate

4 = Severe

**INSTABILITY**

0 = Stable

1 = Unstable

2 = Decomposed

3 = Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate 3 = Serious 4 = Severe
5. FIRE-FIGHTING MEASURES, continued

SPECIAL HAZARDS ARISING FROM THE SUBSTANCE: This product presents a moderate eye and skin-contact hazard to firefighters. This material must be substantially preheated before ignition to occur. When involved in a fire, this material may decompose and produce irritating vapors and toxic gases (including silicon, nitrogen and carbon oxides).

Explosion Sensitivity to Mechanical Impact: Not applicable.
Explosion Sensitivity to Static Discharge: Vapors may be sensitive to static discharge if water has evaporated.

SPECIAL PROTECTIVE ACTIONS FOR FIRE-FIGHTERS: Structural fire-fighters must wear Self-Contained Breathing Apparatus and full protective equipment. Chemical resistant clothing may be necessary. Move containers from fire area if it can be done without risk to personnel. Water spray can be used to cool fire-exposed containers. If possible, prevent runoff water from entering storm drains, bodies of water, or other environmentally sensitive areas. Rinse contaminated equipment thoroughly with soapy water before returning such equipment to service.

6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS AND EMERGENCY PROCEDURES: Proper protective equipment should be used. In the event of a spill, clear the area and protect people. Eliminate all sources of ignition before cleanup begins. Use non-sparking tools. The atmosphere must have levels of components lower than those listed in Section 8, (Exposure Controls and Personal Protective Equipment) if applicable, and have at least 19.5 percent oxygen before personnel can be allowed into the area without Self-Contained Breathing Apparatus (SCBA).

PERSONAL PROTECTIVE EQUIPMENT: Use proper protective equipment and non-sparking tools and equipment.

Small Spills: Wear rubber gloves, splash goggles, and appropriate body protection.
Large Spills: Minimum Personal Protective Equipment should be rubber gloves, rubber boots, face shield, and Tyvek suit. Minimum level of personal protective equipment for releases in which the level of oxygen is less than 19.5% or is unknown must be Level B: triple-gloves (rubber gloves and nitrile gloves over latex gloves), chemical resistant suit and boots, hard hat, and Self-Contained Breathing Apparatus.

METHODS FOR CLEAN-UP AND CONTAINMENT: Avoid allowing contact with water on spilled substance or inside containers.

Small Spills: Absorb spilled material with poly pads or other suitable, non-reacting sorbent, avoiding generation of aerosols, wearing gloves, goggles and apron. Place spilled material in appropriate container for disposal, sealing tightly. Remove all residue before decontamination of spill area.
Large Spills: Access to the spill area should be restricted. Spread should be limited by diking spill area. Absorb spilled liquid with poly pads or other suitable absorbent materials.
All Spills: Place all spill residue in a double plastic bag or other containment and seal. Decontaminate the area thoroughly. Do not mix with wastes from other materials. Dispose of in accordance with applicable Federal, State, and local procedures (see Section 13, Disposal Considerations). For spills on water, contain, minimize dispersion and collect. Dispose of recovered material and report spill per regulatory requirements.

ENVIRONMENTAL PRECAUTIONS: Avoid release to the environment. Run-off water may be contaminated by other materials and should be contained to prevent possible environmental damage.

REFERENCE TO OTHER SECTIONS: See information in Section 8 (Exposure Controls – Personal Protection) and Section 13 (Disposal Considerations) for additional information.

7. HANDLING and USE

PRECAUTIONS FOR SAFE HANDLING: All employees who handle this material should be trained to handle it safely. Keep container tightly closed when not in use. As with all chemicals, avoid getting this product ON YOU or IN YOU. Wash thoroughly after handling this product. Do not eat, drink, smoke, or apply cosmetics while handling this product. Avoid breathing vapors or mists generated by this product. Use in a well-ventilated location. Remove contaminated clothing immediately.

CONDITIONS FOR SAFE STORAGE: Store containers in a cool, dry location, away from direct sunlight, sources of intense heat, or where freezing is possible. Material should be stored in secondary containers or in a diked area, as appropriate. Inspect all incoming containers before storage, to ensure containers are properly labeled and not damaged.

CONDITIONS FOR SAFE STORAGE (continued): Containers should be separated from oxidizing materials by a minimum distance of 20 ft. or by a barrier of non-combustible material at least 5 ft. high having a fire-resistance rating of at least 0.5 hours. Storage areas should be made of fire resistant materials. Local Fire Departments should be notified of the storage of this product on site. Storage and processing areas of this product should be identified with a NFPA 704 placard (diamond) large enough to be seen from a distance. Post warning and “NO SMOKING” signs in storage and use areas, as appropriate. Refer to NFPA 30, Flammable and Combustible Liquids Code, for additional information on storage. Have appropriate extinguishing equipment in the storage area (such as sprinkler systems or portable fire extinguishers). Inspect all incoming extinguishing equipment in the storage area (such as sprinkler systems or portable fire extinguishers). Inspect all incoming containers before storage to ensure containers are properly labeled and not damaged. Empty containers may contain residual product; therefore, empty containers should be handled with care.

SPECIFIC END USE(S): This product is used for cleaning and restoring plastic surfaces. Follow all industry standards for use of this product.
PROTECTIVE PRACTICES DURING MAINTENANCE OF CONTAMINATED EQUIPMENT: Follow practices indicated in Section 6 (Accidental Release Measures). Make certain that application equipment is locked and tagged-out safely. Always use this product in areas where adequate ventilation is provided. Decontaminate equipment thoroughly, before maintenance begins. Collect all rinsates and dispose of according to applicable Federal, State, or local procedures, or applicable standards.

8. EXPOSURE CONTROLS - PERSONAL PROTECTION

VENTILATION AND ENGINEERING CONTROLS: Use with adequate ventilation. Use a mechanical fan or vent area to outside. Use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits provided in this section, if applicable. Use a non-sparking, grounded, explosion-proof ventilation system separate from other exhaust ventilation systems. Exhaust system in manner consistent with prevention of release to atmosphere. An eyewash and safety shower should be readily accessible.

EXPOSURE LIMITS/CONTROL PARAMETERS:

<table>
<thead>
<tr>
<th>CHEMICAL NAME</th>
<th>CAS #</th>
<th>EXPOSURE LIMITS IN AIR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ACGIH-TLVs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (mg/m³)</td>
</tr>
<tr>
<td>Amorphous Silica</td>
<td>68855-54-9</td>
<td>NE</td>
</tr>
<tr>
<td>Crystalline Silica</td>
<td>14808-60-7</td>
<td>NE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crystalline Silica, Cristobalite</td>
<td>14464-46-1</td>
<td>0.025 (resp. fract.)</td>
</tr>
<tr>
<td>Diatomaceous Earth</td>
<td>61790-53-2</td>
<td>NE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mineral Spirits</td>
<td>64742-48-9</td>
<td>NE</td>
</tr>
<tr>
<td>Morpholine</td>
<td>110-91-8</td>
<td>71 (skin)</td>
</tr>
<tr>
<td>Oleic Acid</td>
<td>112-80-1</td>
<td>NE</td>
</tr>
<tr>
<td>Polydimethyl Siloxane</td>
<td>63148-62-9</td>
<td>NE</td>
</tr>
</tbody>
</table>

INTERNATIONAL EXPOSURE LIMITS: Currently, the following international exposure limits are in force for the components of this product. Exposure limits change and should be checked.

CRYSTALLINE SILICA:

- Australia: TWA = 0.1 mg/m³, JUL 2008
- Belgium: TWA = 0.1 mg/m³ (respirable), MAR 2002
- Denmark: TWA = 0.1 mg/m³ (respirable), OCT 2002
- Denmark: TWA = 0.3 mg/m³ (total), OCT 2002
- Finland: TWA = 0.05 mg/m³, resp. dust, SEP 2009
- France: VME = 0.1 mg/m³, (resp), FEB 2006
- Japan: OEL-C = 0.03 mg/m³ (respirable), APR 2007
- Korea: TWA = 0.1 mg/m³, 2006
- Mexico: TWA = 0.1 mg/m³ (respirable), 2004
- The Netherlands: MAC-TGG = 0.075 mg/m³, 2003
- New Zealand: TWA = 0.2 mg/m³ (respirable dust), JAN 2002
- Norway: TWA = 0.1 mg/m³ (resp. dust), JAN 1999
- Norway: TWA = 0.3 mg/m³ (total dust), JAN 1999
- Russia: TWA = 1 mg/m³, STEL = 3 mg/m³, JUN 2003
- Sweden: TWA = 0.1 mg/m³ (resp. dust), JUN 2005
- Switzerland: MAK-W = 0.15 mg/m³, DEC 2006
- Thailand: TWA = 10 mg/m³ (resp. dust), JAN 1993
- Thailand: TWA = 30 mg/m³ (total dust), JAN 1993
- United Kingdom: TWA = 0.3 mg/m³ (respirable), 2005
- In Argentina, Bulgaria, Colombia, Jordan, Singapore, Vietnam check ACGIH TLV

CRYSTALLINE SILICA (continued):

- Australia: TWA = 0.1 mg/m³, JUL 2008
- Austria: TWA = 0.1 mg/m³, MAR 2002
- Belgium: TWA = 0.1 mg/m³ (resp. dust), MAR 2002
- Denmark: TWA = 0.1 mg/m³ (respirable), OCT 2002
- Finland: TWA = 0.05 mg/m³, resp. dust, SEP 2009
- France: VME = 0.1 mg/m³, (resp), FEB 2006
- Japan: OEL-C = 0.03 mg/m³ (respirable), APR 2007
- Korea: TWA = 0.1 mg/m³, 2006
- Mexico: TWA = 0.1 mg/m³ (respirable), 2004
- The Netherlands: MAC-TGG = 0.075 mg/m³, 2003
- New Zealand: TWA = 0.2 mg/m³ (respirable dust), JAN 2002
- Norway: TWA = 0.1 mg/m³ (resp. dust), JAN 1999
- Norway: TWA = 0.3 mg/m³ (total dust), JAN 1999
- Russia: TWA = 1 mg/m³, STEL = 3 mg/m³, JUN 2003
- Sweden: TWA = 0.1 mg/m³ (resp. dust), JUN 2005
- Switzerland: MAK-W = 0.15 mg/m³, DEC 2006
- Thailand: TWA = 10 mg/m³ (resp. dust), JAN 1993
- Thailand: TWA = 30 mg/m³ (total dust), JAN 1993
- United Kingdom: TWA = 0.3 mg/m³ (respirable), 2005
- In Argentina, Bulgaria, Colombia, Jordan, Singapore, Vietnam check ACGIH TLV

CRYSTALLINE SILICA, CRISTOBALITE:

- Australia: TWA = 0.1 mg/m³, JUL 2008
- Austria: TWA = 0.1 mg/m³, MAR 2002
- Belgium: TWA = 0.1 mg/m³ (resp. dust), MAR 2002
- Denmark: TWA = 0.1 mg/m³ (respirable), OCT 2002

NE = Not Established. See Section 16 for Definitions of Terms Used.
EXPOSURE LIMITS/CONTROL PARAMETERS (continued):

INTERNATIONAL EXPOSURE LIMITS (continued):

<table>
<thead>
<tr>
<th>CRYSTALLINE SILICA, CRISTOBALITE (continued):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark: TWA = 0.3 mg/m³ (total), OCT 2002</td>
</tr>
<tr>
<td>Finland: TWA = 0.05 mg/m³, resp. dust, SEP 2009</td>
</tr>
<tr>
<td>France: VME = 0.1 mg/m³ (resp), FEB 2006</td>
</tr>
<tr>
<td>Japan: OEL-C = 0.03 mg/m³ (respirable), APR 2007</td>
</tr>
<tr>
<td>Korea: TWA = 0.1 mg/m³, 2006</td>
</tr>
<tr>
<td>Mexico: TWA = 0.1 mg/m³ (respirable), 2004</td>
</tr>
<tr>
<td>The Netherlands: MAC-TGG = 0.075 mg/m³, 2003</td>
</tr>
<tr>
<td>New Zealand: TWA = 0.2 mg/m³ (respirable dust), JAN 2002</td>
</tr>
<tr>
<td>Norway: TWA = 0.1 mg/m³ (resp. dust), JAN 1999</td>
</tr>
<tr>
<td>Russia: STEL = 1 mg/m³ (total dust), JUN 2003</td>
</tr>
<tr>
<td>Sweden: TWA = 0.1 mg/m³ (resp. dust), JUN 2005</td>
</tr>
<tr>
<td>Switzerland: MAK-W = 0.15 mg/m³, DEC 2006</td>
</tr>
<tr>
<td>Thailand: TWA = 10 mg/m³, JAN 1993</td>
</tr>
<tr>
<td>United Kingdom: TWA = 0.3 mg/m³ (respirable), 2005</td>
</tr>
<tr>
<td>In Argentina, Bulgaria, Colombia, Jordan, Singapore, Vietnam check ACGIH TLV</td>
</tr>
</tbody>
</table>

DIATOMACEOUS EARTH (continued):

| Australia: TWA 10 mg/m³, JUL 2008 |
| Belgium: TWA 10 mg/m³, MAR 2002 |
| Denmark: TWA 1.5 mg/m³ (respirable, with no quartz), OCT 2002 |
| Finland: TWA 5 mg/m³, SEP 2009 |
| Germany: MAK = 4 mg/m³ (inhalable), 2005 |
| Korea: TWA = 10 mg/m³, 2006 |
| Mexico: TWA = 10 mg/m³ (inhalable), 2004 |
| Mexico: TWA = 3 mg/m³ (respirable), 2004 |
| New Zealand: TWA = 10 mg/m³ (inspirable dust), JAN 2002 |
| Norway: TWA = 1.5 mg/m³ (resp. dust), JAN 1999 |
| Switzerland: MAK-W = 4 mg/m³, DEC 2006 |
| Thailand: TWA = 80 mg/m³, JAN 1993 |

ENVIRONMENTAL EXPOSURE CONTROLS: Refer to Sections 6, 7 and 13 for information on controlling exposure to this product to the environment.

PROTECTIVE EQUIPMENT: The following information on appropriate Personal Protective Equipment is provided to assist employers in complying with OSHA regulations found in 29 CFR Subpart I (beginning at 1910.132, including equivalent standards of Canada (including CSA Respiratory Standard Z94.4-02, Z94.3-M1982, Industrial Eye and Face Protectors and CSA Standard Z195-02, Protective Footwear). Please reference applicable regulations and standards for relevant details.

RESPIRATORY PROTECTION: Maintain the Oxygen level above 19.5% in the workplace and exposure limits below levels given earlier in this section, if applicable. Oxygen levels below 19.5% are considered IDLH by OSHA. In such atmospheres, use of a full-facepiece pressure/demand SCBA or a full facepiece, supplied air respirator with auxiliary self-contained air supply is required under OSHA’s Respiratory Protection Standard. If necessary, use only respiratory protection authorized in appropriate regulations to assist in equipment selection. The following are NIOSH respiratory protection guidelines for crystalline silica, in the event that this product contains Breathing Apparatus (SCBA) with a full facepiece, or any SAR with a full facepiece. Also provided are guidelines for Morpholine. These guidelines are given to assist in selection of respiratory protective equipment.

CRYSTALLINE SILICA

<table>
<thead>
<tr>
<th>CONCENTRATION</th>
<th>RESPIRATORY PROTECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 0.5 mg/m³;</td>
<td>Any Air-Purifying Respirator with a high-efficiency particulate filter.</td>
</tr>
<tr>
<td>Up to 1.25 mg/m³;</td>
<td>Any Powered, Air-Purifying Respirator (PAPR) with a high-efficiency particulate filter, or any Supplied-Air Respirator (SAR) operated in a continuous-flow mode.</td>
</tr>
<tr>
<td>Up to 2.5 mg/m³;</td>
<td>Any Air-Purifying, Full-Facepiece Respirator with a high-efficiency particulate filter, or any PAPR with a tight-fitting facepiece and a high-efficiency particulate filter.</td>
</tr>
<tr>
<td>Up to 25 mg/m³;</td>
<td>Any SAR operated in a pressure-demand or other positive-pressure mode.</td>
</tr>
<tr>
<td>Emergency or Planned Entry into Unknown Concentrations or IDLH Conditions: Any SCBA that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode, or any SAR that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary SCBA operated in pressure-demand or other positive-pressure mode.</td>
<td></td>
</tr>
<tr>
<td>Escape:</td>
<td>Any Air-Purifying, Full-Facepiece Respirator with a high-efficiency particulate filter, or any appropriate escape-type, SCBA.</td>
</tr>
</tbody>
</table>

MORPHOLINE

<table>
<thead>
<tr>
<th>CONCENTRATION</th>
<th>RESPIRATORY PROTECTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 500 ppm;</td>
<td>Any Supplied-Air Respirator (SAR) operated in a continuous-flow mode, or any Powered Air-Purifying Respirator (PAPR) with organic vapor cartridge(s), or any Air-Purifying Full-Facepiece Respirator equipped with organic vapor cartridge(s), or any Air-Purifying, Full-Facepiece Respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister, or any PAPR with a tight-fitting facepiece and organic vapor cartridge(s), or any Self-contained Breathing Apparatus (SCBA) with a full facepiece, or any SAR with a full facepiece.</td>
</tr>
<tr>
<td>Up to 1, 400 ppm;</td>
<td>Any Supplied-Air Respirator (SAR) that has a full facepiece and is operated in a pressure-demand or other positive pressure mode.</td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS - PERSONAL PROTECTION (Continued)

RESPIRATORY PROTECTION (continued):

Morpholine (continued)

Concentration: Respiratory Protection

Emergency or Planned Entry into Unknown Concentrations or IDLH Conditions: Any SCBA that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode, or any SAR that has a full-facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained breathing apparatus operated in pressure-demand or other positive-pressure mode.

Escape: Any Air-Purifying, Full-Facepiece Respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister, or any appropriate escape-type, SCBA.

Eye Protection: Use approved safety goggles or safety glasses. If necessary, refer to appropriate regulations to assist in equipment selection.

Hand Protection: Wear butyl rubber, Teflon™, Barricade™, Chemrel™, nitrile or similar gloves for routine industrial use. Use triple gloves for spill response, as stated in Section 6 (Accidental Release Measures) of this SDS. If necessary, refer to applicable regulations and standards.

Body Protection: Use body protection appropriate for task. Safety shoes are recommended when handling cylinders. If a hazard of injury to the feet exists due to falling objects, rolling objects, where objects may pierce the soles of the feet or where employee's feet may be exposed to electrical hazards, use foot protection. If necessary, refer to appropriate regulations to assist in equipment selection.

9. PHYSICAL and CHEMICAL PROPERTIES

Physical State: Viscous liquid.

Molecular Formula: Mixture.

Odor: Hydrocarbon.

Odor Threshold: Not established for product.

Relative Vapor Density (air = 1): > 1.0

Evaporation Rate (nBuAc = 1): < 1.0

Specific Gravity (water = 1): 1.01

Melting/Freezing Point: Not established for product.

Solubility in Water: Soluble.

Boiling Point: 80°C (176°F)

Vapor Pressure, mm Hg @ 50°C: < 75

pH: 8.5 to 9.0

% Volatile: < 16

Coefficient of Oil/Water Distribution (Partition Coefficient): Not established.

How to Detect This Substance (identification/warning properties): The odor is a distinguishing characteristic of this product.

10. STABILITY and REACTIVITY

Chemical Stability: Stable under typical, environmental conditions in a workplace in the absence of contaminants.

Decomposition Products:
- Combustion: Silicon, nitrogen and carbon oxides.
- Hydrolysis: None known.

Materials with Which Substance is Incompatible: Strong oxidizers, strong acids, strong bases.

Possibility of Hazardous Reactions: None known.

Conditions to Avoid: Exposure to water, moist air, and ultraviolet light, incompatible chemicals, high temperatures.

11. TOXICOLOGICAL INFORMATION

Symptoms of Overexposure by Route of Exposure:

Inhalation: Inhalation is not anticipated to be a significant route of overexposure to this product. If mists of this product are inhaled, irritation of the nose and other tissues of the upper respiratory system may occur. Inhalation of high concentrations of vapors (as may occur if this material is used in a poorly ventilated area), symptoms of central nervous system depression (e.g., headaches, dizziness, nausea) can result. Symptoms are generally alleviated upon breathing fresh air. This product may contain Crystalline Silica, which is known to cause cancer by inhalation. If this product is used in a manner that creates dust (such as application of product with a mechanical polishing wheel), use of respiratory protection is required.

Contact with Skin or Eyes: Depending on the duration and concentration of overexposure, eye contact can cause irritation and reddening. Skin contact can cause reddening, discomfort, and irritation. Symptoms are generally alleviated upon rinsing.

Skin Absorption: Skin absorption is a potential route of exposure for the Morpholine component of this product. Symptoms of such exposure would include those listed under “Contact with Eyes or Skin”. If a large area of skin is involved, systemic toxicity can occur.

Ingestion: Ingestion is not anticipated to be a likely route of exposure to this product in the workplace. If this material is swallowed, it may cause headache, nausea, and vomiting. While not anticipated to occur, due to product viscosity, aspiration of this liquid may cause life-threatening lung damage.

Injection: Though not anticipated to be a likely route of occupational exposure, injection of this material (via puncture or laceration by a contaminated object) may cause local reddening, tissue swelling, and discomfort in addition to the wound.

Other Health Effects: Components, including Crystalline Silica, are known or suspected carcinogens. This product contains compounds that may damage the lungs through acute and chronic inhalation exposure.
HEALTH EFFECTS OR RISKS FROM EXPOSURE: An Explanation in Lay Terms.

Acute: This material may be irritating to the eyes, skin, and mucous membranes. Inhalation of high concentrations of this product's vapors can cause dizziness, headaches, and nausea. While unlikely, if swallowed, aspiration of this liquid may cause life-threatening lung damage.

Chronic: Repeated skin contact can cause dermatitis (inflammation of the skin, resulting in redness and dryness). Contains compounds with known or suspected carcinogenic effects (see 'Other Health Effects').

TARGET ORGANS: Acute: Skin, eyes, respiratory system. Chronic: Skin, respiratory system.

TOXICITY DATA: The specific toxicology data available for the components of this product present in greater than 1 percent concentration are presented below:

**AMORPHOUS SILICA:**
Currently, there are no toxicological data for this compound.

**CRYSTALLINE SILICA CRISTOBALITE (QUARTZ):**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCLo (Inhalation-Human) 16 mmcf/8 hours</td>
<td>8 hours-intermittent: Systemic effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 50 mg/m³/6 hours</td>
<td>71 weeks-intermittent: Carcinogenic effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 80 mg/m³/26 weeks-intermittent:</td>
<td>Lungs, Thorax, or Respiration: fibrosis, focal (pneumoconiosis); changes in spleen; Immunological including Allergic: decrease in cellular immune response</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 108 mg/m³/6 hours</td>
<td>3 days-intermittent: Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: phosphatases, Enzyme inhibition, induction, or change in blood or tissue levels: other oxidoreductases; Metabolism (Intermediary); other proteins</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 58 mg/m³/13 weeks-intermittent:</td>
<td>Lungs, Thorax, or Respiration: other changes; Endocrine: Changes in spleen weight; Blood: changes in leukocyte (WBC) count</td>
</tr>
<tr>
<td>TCLo (Inhalation-Mouse) 1475 µg/m³/8 hours</td>
<td>21 weeks-intermittent: Lungs, Thorax, or Respiration: other changes</td>
</tr>
<tr>
<td>TCLo (Inhalation-Mouse) 4932 µg/m³/24 hours</td>
<td>39 weeks/continuous: Endocrine: Changes in spleen weight; Immunological including Allergic: decrease in humoral immune response</td>
</tr>
<tr>
<td>TCLo (Inhalation-Guinea Pigs) 28 mg/m³/3 weeks</td>
<td>Continuous: Lungs, Thorax, or Respiration: other changes, changes in lung weight; Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: other</td>
</tr>
<tr>
<td>TCLo (Intratracheal-Rat) 45 mg/kg</td>
<td>Carcinogenic effects</td>
</tr>
<tr>
<td>TCLo (Intratracheal-Rat) 90 mg/kg</td>
<td>Equivocal tumorigenic agent</td>
</tr>
<tr>
<td>TCLo (Intratracheal-Rat) 110 mg/kg</td>
<td>Carcinogenic effects</td>
</tr>
<tr>
<td>TCLo (Intratracheal-Rat) 111 mg/kg</td>
<td>Carcinogenic effects</td>
</tr>
<tr>
<td>TCLo (Intratracheal-Rat) 100 mg/kg/19 weeks</td>
<td>Intermittent: Tumorigenic: equivocal tumorigenic agent by RTECS criteria; Lungs, Thorax, or Respiration: tumors</td>
</tr>
<tr>
<td>TCLo (Intrapleural-Rat) 90 mg/kg</td>
<td>Carcinogenic effects</td>
</tr>
<tr>
<td>TCLo (Intrapleural-Hamster) 83 mg/kg</td>
<td>Tumorigenic: neoplastic by RTECS criteria, tumors at site of application</td>
</tr>
<tr>
<td>TCLo (Intrapleural-Hamster) 83 mg/kg</td>
<td>Tumorigenic: Endocrine: Changes in spleen weight; Blood: Changes in leukocyte (WBC) count</td>
</tr>
<tr>
<td>TCLo (Intrapleural-Hamster) 83 mg/kg</td>
<td>Tumorigenic: Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: other</td>
</tr>
<tr>
<td>TCLo (Intrapleural-Hamster) 83 mg/kg</td>
<td>Tumorigenic: Immunological including Allergic: decreased in cellular immune response</td>
</tr>
</tbody>
</table>

**CRYSTALLINE SILICA (QUARTZ):**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDLo (Intratracheal-Rat) 250 ppm/6 hours</td>
<td>13 weeks-intermittent: Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 200 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 100 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 90 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 0.008 gm/m³</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>Micronucleus Test (Hamster-Lung) 160 µg/cm²</td>
<td>Carcinogenic by RTECS criteria; Blood: Lymphoma; including Hodgkin's disease</td>
</tr>
<tr>
<td>Micronucleus Test (Human-Lung)</td>
<td>40 µg/cm²</td>
</tr>
</tbody>
</table>

**DIATOMACEOUS EARTH:**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDLo (Intratracheal-Rat) 10 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 300 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 150 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 10 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 10 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
</tbody>
</table>

**MORPHOLINE:**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDLo (Intratracheal-Rat) 200 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 100 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 50 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 25 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>LDLo (Intratracheal-Rat) 10 mg/kg</td>
<td>Lungs, Thorax, or Respiration: other changes; Biochemical: Metabolism (Intermediary): effect on inflammation or mediation of inflammation</td>
</tr>
<tr>
<td>Micronucleus Test (Human-Lung)</td>
<td>40 µg/cm²</td>
</tr>
</tbody>
</table>

**MORPHOLINE (continued):**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDLo (Oral-Rat) 700 mg/kg</td>
<td>Reproductive: Maternal Effects: spermatogenesis (incl. genetic material, sperm morphology, motility, and count)</td>
</tr>
<tr>
<td>LDLo (Oral-Rat) 1738 mg/kg</td>
<td>Kidney/Ureter/Bladder: changes in blood vessels or in circulation of kidney</td>
</tr>
<tr>
<td>LDLo (Oral-Mouse) 525 mg/kg</td>
<td>Behavioral: sleep, somnolence (general depressed activity)</td>
</tr>
<tr>
<td>LDLo (Oral-Mouse) 1200 mg/kg</td>
<td>Reproductive: Effects: testes, epididymis, sperm duct</td>
</tr>
<tr>
<td>LDLo (Subcutaneous-Mouse) 458 mg/kg</td>
<td>LD (Oral-Rat) 1500 mg/kg</td>
</tr>
<tr>
<td>LD (Oral-Rat) 2300 mg/kg</td>
<td>Brain and Coverings: changes in circulation (hemorrhage, thrombosis, etc.); Cardio: cardiomyopathy including infarction, other changes</td>
</tr>
<tr>
<td>LC (Inhalation-Mouse) 0.45 gm/m³/2 hours</td>
<td>Blood: hemorrhage; Nutritional and Gross Metabolic: weight loss or decreased weight gain</td>
</tr>
<tr>
<td>LC (Inhalation-Mouse) 1.98 gm/m³/2 hours</td>
<td>Blood: hemorrhage; Nutritional and Gross Metabolic: weight loss or decreased weight gain</td>
</tr>
<tr>
<td>LC (Inhalation-Mouse) 1.98 gm/m³/2 hours</td>
<td>Blood: hemorrhage; Nutritional and Gross Metabolic: weight loss or decreased weight gain</td>
</tr>
</tbody>
</table>

**PHYSICAL HAZARD:**

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Hazard Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCLo (Inhalation-Rat) 100 ppm</td>
<td>Acute: respiratory effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 10 mg/cm³</td>
<td>Acute: respiratory effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 30 mg/cm³</td>
<td>Acute: respiratory effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 10 mg/cm³</td>
<td>Acute: respiratory effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 30 mg/cm³</td>
<td>Acute: respiratory effects</td>
</tr>
<tr>
<td>TCLo (Inhalation-Rat) 10 mg/cm³</td>
<td>Acute: respiratory effects</td>
</tr>
</tbody>
</table>

**OTHER INFORMATION:**

For Routine Industrial Use and Handling Applications.

**Hazard Scale:** 0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe; 5 = Chronic hazard.

**Toxicity Index:**

1. **FLAMMABILITY HAZARD (RED):** 1
2. **PHYSICAL HAZARD (YELLOW):** 0
3. **HAZARDOUS MATERIAL IDENTIFICATION SYSTEM:**
   - **HEALTH HAZARD:** (BLUE) 2°
TOXICITY DATA (continued):

MORPHOLINE (continued):
TCLo (Inhalation-Rat) 0.07 gm/m³/30 days-intermittent; Blood: changes in other cell types (unspecified)
TCLo (Inhalation-Rat) 0.008 gm/m³/122 days-intermittent; Blood: changes in spleen; Immunological Including Allergic: decrease in cellular immune response
TCIlo (Inhalation-Mouse) 0.1 gm/m³/2 hours; Lungs, Thorax, or Respiration: other changes
TCIlo (Inhalation-Guinea Pig) 70 mg/m³/4 hours/17 weeks-intermittent; Liver: liver function tests impaired; Kidney/Ureter/Bladder: other changes in urine composition
TCIlo (Inhalation-Guinea Pig) 0.07 gm/m³/2 weeks-intermittent; Peripheral Nerve and Sensation: recording from a peripheral motor nerve
TCLo (Inhalation-Guinea Pig) 0.07 gm/m³/30 days-intermittent; Blood: other changes, changes in leukocyte (WBC) count
TCLo (Inhalation-Guinea Pig) 0.008 gm/m³/61 days-intermittent; Liver: liver function tests impaired; Kidney/Ureter/Bladder: other changes in urine composition
TDLo (Oral-Rat) 24 gm/kg/30 days-intermittent; Gastrointestinal: necrotic changes; Kidney/Ureter/Bladder: changes in tubules (including acute renal failure, acute tubular necrosis); Related to Chronic Data: death
TDLo (Oral-Rat) 500 mg/kg
TDLo (Oral-Mouse) 2560 mg/kg/1 year-continuous; Tumorogenic: neoplastic by RTECS criteria; Lungs, Thorax, or Respiration: respiratory depression; Related to Chronic Data: death
TDLo (Oral-Guinea Pig) 13,500 mg/kg/30 days-intermittent; Gastrointestinal: necrotic changes; Kidney/Ureter/Bladder: changes in tubules (including acute renal failure, acute tubular necrosis); Related to Chronic Data: death
TDLo (Skin-Rabbit) 9 gm/kg/10 days-intermittent; Liver: fatty liver degeneration; Skin and Appendages: primary irritation (after topical exposure); Related to Chronic Data: death
TDLo (Skin-Mouse) 100 ppm/15 minutes; Skin and Appendages: corrosive (after topical exposure)
TDLo (Skin-Guinea Pig) 27 gm/kg/30 days-intermittent; Kidney/Ureter/Bladder: changes in both tubules and glomeruli; Skin and Appendages: primary irritation (after topical exposure); Related to Chronic Data: death
TDLo (Ocular-Rabbit) 100 ppm; Sense Organs and Special Senses (Eye): conjunctiva irritation, corneal damage, effect, not otherwise specified
LDLo (Oral-Mouse) 1200 mg/kg
LDLo (Oral-Guinea Pig) 100 mg/kg; Sense Organs and Special Senses (Olfaction); effect, not otherwise specified
Gastrointestinal: ulceration or bleeding from stomach, ulceration or bleeding from small intestine
LDLo (Unreported-Rat) 1600 mg/kg
Morphological Transformation (Mouse-Fibroblast) 125 mg/L

MORPHOLINE (continued):
Morphological Transformation (Mouse-Lymphocyte) 1 L/L
Mutation in Mammalian Somatic Cells (Mouse-Lymphocyte) 1 gm/L
Sister Chromatid Exchange (Hamster Ovary) 160 mg/L
Cytogenetic Analysis (Inhalation-Rat) 0.07 mg/L/122 days-intermittent

MINERAL SPIRITS:
Currently, there are no toxicological data for this compound.

OLEIC ACID:
Standard Draize Test (Skin-Human) 15 gm/3 days-intermittent; Moderate
Standard Draize Test (Eye-Rabbit) 100 mg; Mild
Open Irritation Test (Skin-Rabbit) 500 mg; Mild
LD50 (Oral-Rat) 25,000 mg/kg
LD0 (Oral-Mouse) 28,000 mg/kg (Intravenous-Rat) 2400 µg/kg; Lungs, Thorax, or Respiration: acute pulmonary edema, other changes
LD50 (Intravenous-Mouse) 230 mg/kg; Behavioral: convulsions or effect on seizure threshold
LD50 (Intraperitoneal-Mouse) 282 mg/kg
LD (Intravenous-Rabbit) > 55 mg/kg; Lungs, Thorax, or Respiration: other changes
LD (Intravenous-Monkey) > 40 µL/kg; Lungs, Thorax, or Respiration: other changes; Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: dehydrogenases, other Enzymes
TDLo (Skin-Mouse) 1500 mg/kg/3 days-intermittent; Blood: other changes
TDLo (Intravenous-Mouse) 8 mL/kg/10 days-intermittent; Tumorogenic: carcinogenic by RTECS criteria; Skin and Appendages: tumors; Tumorogenic: facilitates action of known carcinogen
TDLo (Intravenous-Rat) 0.15 mL/kg; Lungs, Thorax, or Respiration: acute pulmonary edema, other changes, changes in lung weight
TDLo (Intravenous-Rat) 100 mg/kg; Lungs, Thorax, or Respiration: changes in pulmonary vascular resistance, acute pulmonary edema, other changes
TDLo (Intravenous-Rat) 100 mg/kg; Blood: hemorrhage, changes in serum composition (e.g. TP, bilirubin, cholesterol); Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels; other oxidoreductases
TDLo (Intravenous-Rat) 15 µL/kg; Lungs, Thorax, or Respiration: changes in pulmonary vascular resistance, respiratory depression
TDLo (Intravenous-Dog) 0.08 mg/kg; Lungs, Thorax, or Respiration: respiratory depression, other changes; Blood: other changes
TDLo (Intravenous-Monkey) 0.08 mg/kg; Immunological Including Allergic: increase in humoral immune response; Biochemical: Metabolism (Immunological): Other
TDLo (Intradermal-Guinea Pig) 400 µg/kg; Immunological Including Allergic: hypersensitivity delayed

OLEIC ACID (continued):
TDLo (Intraperitoneal-Mouse) 2712 mg/kg/6 weeks-intermittent; Immunological Including Allergic: autoimmune
TDLo (Subcutaneous-Rabbit) 390 mg/kg/17 weeks-intermittent; Tumorogenic: equivocal tumorigenic agent by RTECS criteria, tumors at site of application
TDLo (Inhalation-Rat) 30 mg/m³/4 hours; Behavioral: alteration of classical conditioning; Blood: changes in serum composition (e.g. TP, bilirubin, cholesterol); Immunological Including Allergic: hypersensitivity delayed
Cytogenetic Analysis (Yeast-Saccharomyces cerevisiae) 100 mg/L
Cytogenetic Analysis (Hamster Fibroblast) 2500 µL/g
Unscheduled DNA Synthesis (Rectal-Mouse) 35 mg/kg

POLYDIMETHYL SILXON:
Standard Draize Test (Skin-Rabbit) 500 µL/24 hours; Mild
Standard Draize Test (Eye-Rabbit) 100 µL/24 hours; Mild
LDLo (Oral-Rat) > 24 gm/kg; Gastrointestinal: hypermotility, diarrhea
LDLo (Oral-Rat) > 17 gm/kg; Kidney/Ureter/Bladder: other changes; Nutritional and Gross Metabolic: other changes
LDLo (Skin-Rabbit) > 2 gm/kg; Behavioral: food intake (animal); Gastrointestinal: hypermotility, diarrhea; Skin and Appendages: dermatitis, other (after systemic exposure)
LD (Oral-Rat) > 5 gm/kg
LD (Intramuscular-Rat) > 1200 µL/kg; Immunological Including Allergic: increase in humoral immune response
LD (Skin-Rabbit) > 10.200 mg/kg
LDLo (Intraperitoneal-Mouse) 16 mL/kg; Gastrointestinal: hypermotility, diarrhea, Immunological Including Allergic: decrease in cellular; decrease in humoral immune response
TDLo (Oral-Rat) 1800 mL/kg/26 weeks-continuous; Lungs, Thorax, or Respiration: changes in lung weight; Liver: changes in liver weight; Kidney/Ureter/Bladder: other changes in urine composition
LDLo (Oral-Rat) 227 gm/kg; Sense Organs and Special Senses (Eye): corneal damage; Behavioral: food intake (animal); Blood: changes in serum composition (e.g. TP, bilirubin, cholesterol)
TDLo (Subcutaneous-Rat) 10 gm/kg; female 6-15 day(s) after conception; Reproductive: Specific Developmental Abnormalities: musculoskeletal system
TDLo (Subcutaneous-Rat) 8 gm/kg; female 15-22 day(s) after conception; Reproductive: Effects on Embryo or Fetus; lethal death; Reproductive: Specific Developmental Abnormalities: body wall

CARCINOGENIC POTENTIAL OF COMPONENTS: Components of this product are listed by agencies tracking the carcinoogenic potential of chemical compounds, as follows:

CRYSSTALLINE SILICA: ACGIH TLV-A2 (Suspected Human Carcinogen); IARC-1 (Carcinogenic to Humans); NIOSH-Ca (Potential Occupational Carcinogenic, with No Further Categorization); Respirable Fraction: MAK-1 (Substances that Cause Cancer in Man and Can Be Assumed to Make a Significant Contribution to Cancer Risk); NTP-K (Known to Be a Human Carcinogen)

CRYSSTALLINE SILICA, CRISTOBALITE: ACGIH TLV-A2 (Suspected Human Carcinogenicity); IARC-1 (Carcinogenic to Humans); NIOSH-Ca (Potential Occupational Carcinogenic, with No Further Categorization); Respirable Fraction: MAK-1 (Substances that Cause Cancer in Man and Can Be Assumed to Make a Significant Contribution to Cancer Risk); NTP-K (Known to Be a Human Carcinogen)

MORPHOLINE: ACGIH TLV-A4 (Not Classifiable as a Human Carcinogen); IARC-3 (Unclassifiable as to Carcinogenicity in Humans)

OLEIC ACID: MAK-3A (Substances for Which the Criteria for Classification in Category 4 or 5 are fulfilled, but for which the database is insufficient for the establishment of a MAK value)

The remaining components are not found on the following lists: U.S. EPA, U.S. N.T., U.S. OSHA, U.S. NIOSH, IARC, GERMAN MAK, and AGHIH, and therefore are neither considered to be nor suspected to be cancer-causing agents by these agencies.

IRRITATION OF PRODUCT: This product can be mildly irritating to contaminated eyes, skin and mucous membranes.

SENSITIZATION TO THE PRODUCT: Components of this product are not known to cause human skin or respiratory sensitization.
11. TOXICOLOGICAL INFORMATION (Continued)

REPRODUCTIVE TOXICITY INFORMATION: Currently, there is no information on the potential human mutagenic, embryotoxic, teratogenic or reproductive effects from this product. Animal data from the Morpholine component has shown both positive and negative mutagenic results, with no conclusions possible on mutagenicity. The Mineral Spirits component is classified under European regulations as a potential mutagenic compound, although no data is available to support this classification.

BIOLOGICAL EXPOSURES INDICES (BEIs): Currently, there are no ACGIH Biological Exposure Indices (BEIs) determined for the components of this product.

12. ECOLOGICAL INFORMATION

ALL WORK PRACTICES MUST BE AIMED AT ELIMINATING ENVIRONMENTAL CONTAMINATION.

MOBILITY: This product has not been tested for mobility in soil. The following information is available for some components.

MORPHOLINE:
Using a measured log octanol/water partition coefficient (log Kow) of -0.86 and a regression and a regression equation, the estimated Koc for this compound is 8. The Koc estimated from molecular structure is 8. According to a suggested classification scheme, this estimated Koc suggests that this compound is highly mobile in soil.

OLEIC ACID:
The Koc of undissociated oleic acid is estimated as 340,000, using a log Kow of 7.64 and a regression-derived equation. According to a classification scheme, this estimated Koc value suggests that this compound is expected to be immobile in soil. The pKa of oleic acid is 5.02, indicating that this compound will exist almost entirely in anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts.

PERSISTENCE AND BIODEGRADABILITY: This product has not been tested for persistence or biodegradability. The following information is available for some components.

MORPHOLINE:
If released to soil, this compound may volatilize from dry soil surfaces, but not from moist soil. This material in soil will move with soil moisture and is expected to leach extensively. Based on screening test results, biodegradation may be significant, but only after a long adaptation period. When released to natural waters this material will not tend to bioconcentrate, volatilize, or sorb to sediment or organic particulate matter in the water column. While morpholine is biodegradable in screening tests, it is unlikely that significant morpholine degradation would occur because of the long lag period required. This compound reacts with photochemically-produced hydroxyl radicals in the atmosphere resulting in an estimated half-life of 2.6 hrs.

OLEIC ACID:
If released to air, a vapor pressure of 5.46X10^-7 mm Hg at 25°C indicates this compound will exist in both the vapor and particulate phases in the atmosphere. Vapor-phase material will be degraded in the atmosphere by reaction with ozone; half-lives of about 2.1 and 1.4 hours for the cis- and trans- isomers, respectively, are calculated for this reaction. Particulate-phase oleic acid will be removed from the atmosphere by wet or dry deposition. This compound does not contain chromophores that absorb at wavelengths > 290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, undissociated material is expected to have no mobility based upon an estimated Koc of 340,000. The pKa of oleic acid is 5.02, indicating that this compound will exist almost entirely in anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Biodegradation is expected to be an important fate process in soil based on half-lives of 0.2 and 0.66 days in screening tests. If released into water, undissociated this compound is expected to adsorb to suspended solids and sediment based upon the estimated Koc. This material was biodegraded 25-30% in the water column in field studies. Based upon the pKa this material will exist almost entirely in the anion form at pH values of 5 to 9 and therefore volatilization from water surfaces is not expected to be an important fate process.

BIO-ACCUMULATION POTENTIAL: This product has not been tested for bio-accumulation potential. The following is information for some components.

MORPHOLINE:
Because this compound is miscible with water and has a very low measured octanol/water partition coefficient, log Kow -0.86, its tendency to bioconcentrate in aquatic organisms should be extremely low. An experimentally determined BCF for morpholine was < 2.8.

OLEIC ACID:
An estimated BCF of 10 was calculated in fish for this compound, using a log Kow of 7.64 and a regression-derived equation. According to a classification scheme, this BCF suggests the potential for bioconcentration in aquatic organisms is low.

ECOTOXICITY: This product may have significant, adverse effects on aquatic plants and animals if incidentally released to an aquatic environment. The following are aquatic toxic data for some components of this product. Limited data are presented in this SDS. Contact Novus for information on additional data.

MORPHOLINE:
LC50 (bluegill) 96 hours = 350 mg/L
LC50 (daphnia) 24 hours = 100 mg/L
EC50 (Daphnia magna) 24 hours = 119 mg/L (immobilization)

OLEIC ACID:
LC50 (Pimephales promelas Fathead minnow, juvenile 4-8 wk, length 1.1-3.1 cm) 96 hours = 205,000 µg/L; Conditions: freshwater, static, 18-22°C, dissolved oxygen < or =4.0 mg/L

OTHER ADVERSE EFFECTS: Components of this product are not listed as having ozone depletion potential.

ENVIRONMENTAL EXPOSURE CONTROLS: Controls should be engineered to prevent release to the environment, including procedures to prevent spills, atmospheric release and release to waterways.

RESULTS OF PBT and vPvB ASSESSMENT: No data available. PBT and vPvB assessments are part of the chemical safety report required for some substances in European Union Regulation (EC) 1907/2006, Article 14.

13. DISPOSAL CONSIDERATIONS

DISPOSAL METHODS: It is the responsibility of the generator to determine at the time of disposal whether the product meets the criteria of a hazardous waste per regulations of the area in which the waste is generated and/or disposed of. Waste disposal must be in accordance with appropriate Federal, State, and local regulations. This product, if unaltered by use, may be disposed of by treatment at a permitted facility or as advised by your local hazardous waste regulatory authority. Shipment of wastes must be done with appropriately permitted and registered transporters.

DISPOSAL CONTAINERS: Waste materials must be placed in and shipped in impermeable containers (such as poly or metal waste pails or drums). Permeable cardboard containers are not appropriate and should not be used. Ensure that any required marking or labeling of the containers be done to all applicable regulations.

PRECAUTIONS TO BE FOLLOWED DURING WASTE HANDLING: Wear proper protective equipment when handling waste materials.

U.S. EPA WASTE NUMBER: Not applicable.
14. TRANSPORTATION INFORMATION

U.S. DEPARTMENT OF TRANSPORTATION REGULATIONS: This product is NOT classified as dangerous goods, per U.S. DOT regulations, under 49 CFR 172.101.

TRANSPORT CANADA TRANSPORTATION OF DANGEROUS GOODS REGULATIONS: This product is NOT considered as Dangerous Goods, per regulations of Transport Canada.

INTERNATIONAL AIR TRANSPORT ASSOCIATION DESIGNATION: This material is NOT considered as dangerous goods, per rules of IATA.

INTERNATIONAL MARITIME ORGANIZATION (IMO): This product is NOT considered as dangerous goods, per rules of the IMO.

ENVIRONMENTAL HAZARDS: This product does not meet the criteria of environmentally hazardous according to the criteria of the UN Model Regulations (as reflected in the IMDG Code, ADR, RID, and ADN); components are not specifically listed in Annex III under MARPOL 73/78.

15. REGULATORY INFORMATION

ADDITIONAL U.S. REGULATIONS:

U.S. SARA REPORTING REQUIREMENTS: The components of this product are NOT subject to the reporting requirements of Sections 302, 304, and 313 of Title III of the Superfund Amendments and Reauthorization Act.

U.S. SARA THRESHOLD PLANNING QUANTITY: There are no specific Threshold Planning Quantities for this product. The default Federal SDS submission and inventory requirement filing threshold of 10,000 lb (4,540 kg) may apply, per 40 CFR 370.20.

U.S. CERCLA REPORTABLE QUANTITY (RQ): Not applicable.

U.S. TSCA INVENTORY STATUS: The components of this product listed are listed on the TSCA Inventory.

OTHER U.S. FEDERAL REGULATIONS: Not applicable.

CALIFORNIA SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT (PROPOSITION 65): The Crystalline Silica (airborne particles of respirable size) component of this product is on the California Proposition 65 lists. WARNING! This product contains a compound known to the State of California to cause cancer.

ADDITIONAL CANADIAN REGULATIONS:

CANADIAN DSL/NDSL INVENTORY: The components of this product listed are listed on the DSL Inventory.

CANADIAN WHMIS IDL DISCLOSURE STATUS: The Amorphous Silica/ Diatomaceous Earth Crystalline Silica, Morpholine and Oleic components of this product have a disclosure level of 1%.

OTHER CANADIAN REGULATIONS: Not applicable.

CANADIAN ENVIRONMENTAL PROTECTION AGENCY (CEPA) PRIORITY SUBSTANCES LISTS: The components of this product are not on the Priority Substances Lists.

CANADIAN WHMIS CLASSIFICATION and SYMBOLS: Class D2B (Materials Causing Other Toxic Effects) Irritation.

16. OTHER INFORMATION

OSHA HAZCOM GLOBAL HARMONIZATION LABELING AND CLASSIFICATION: This product would be classified as follows, per OSHA's Hazard Communication Standard (29CFR §1910.1200). This is a self-classification.

Classification: Skin Irritation Category 2, Eye Irritation Category 2A, Specific Target Organ Toxicity (Inhalation-Respiratory Irritation) Single Exposure Category 3, Specific Target Organ Toxicity (Inhalation) Repeated Exposure Category 2

Signal Words: Warning

Hazard Statements: H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. H373: May cause damage to respiratory system through prolonged or repeated exposure by inhalation.

Precautionary Statements:


Disposal: P501: Dispose of contents/containers in accordance with all local, regional, national and international regulations.

Hazard Symbols/Pictograms: GHS07, GHS08
"The information herein is given in good faith, but no warranty, express or implied, is made."